Immunome (IMNM) Operating Expenses (2019 - 2026)

Immunome's Operating Expenses history runs 8 years deep, the most recent figure standing at $59.3 million for Q1 2026.

• Quarterly Operating Expenses rose 24.74% year-over-year to $59.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $242.8 million (up 6.0% YoY) and the FY2025 annual result came in at $231.1 million, down 26.61% from the prior year.
• Operating Expenses was $59.3 million for Q1 2026 at Immunome, down from $72.9 million in the prior quarter.
• Across five years, Operating Expenses topped out at $133.3 million in Q1 2024 and bottomed at $6.8 million in Q1 2023.
• A 5-year average of $45.0 million and a median of $47.6 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses surged 1850.67% — and 2025, when it plunged 64.33%.
• Immunome's Operating Expenses stood at $7.8 million in 2022, then soared by 1164.66% to $98.5 million in 2023, then slipped by 12.97% to $85.7 million in 2024, then fell by 14.99% to $72.9 million in 2025, then dropped by 18.57% to $59.3 million in 2026.
• Business Quant data shows IMNM's Operating Expenses at $59.3 million in Q1 2026, $72.9 million in Q4 2025, and $60.1 million in Q3 2025.